Who we are

About CORONIS

From clinical research to patient support, we advance pharma initiatives at every stage.

1997

Established as a CRO in Athens.

ISO

9001 since 2004. 27001, 37001, 13485 and YA 4822.

HACRO

Founding member. Our CEO has been President since 2017.

EUCROF

Active European member, approved as a CRO by the Greek competent authority.

CORONIS Research is a clinical research and pharma services provider, operating in Greece and Cyprus for 30 years as a trusted partner to pharmaceutical, biotechnology and medical technology companies in their pursuit of advancing products from development to patient access.

Built on a strong foundation in clinical research, the company combines scientific expertise, operational excellence and integrated service capabilities. From clinical research and decentralised trials to regulatory, vigilance, market access, and patient support programs, CORONIS supports clients from development to patient access.

As a founding member of HACRO and an active member of EUCROF, CORONIS stays at the front of regulatory and industry developments across Europe. CORONIS is certified to ISO 9001:2015, ISO 27001, ISO 37001 and ISO 13485, and is approved by the Greek Competent Authority as a CRO.

Milestones

From a CRO in Athens to three countries

1997
Established as a CRO in Athens.
2003
Re-branded as CORONIS Research and acquired the Athens premises.
2004
ISO 9001 certified. Bioequivalence unit opened.
2005
Cyprus affiliate founded.
2019
Bulgarian affiliate founded.
2021
Patient support programs launched.
2022
Home nursing in clinical trials. ISO 27001, 37001 and 13485.

Athens headquarters

A building we own, fitted for the work

Clinical files, investigational product, and training sit in the same privately owned headquarters — not a borrowed floor.

Five-floor, privately owned headquarters in Chalandri, Athens
Dedicated archiving room
Drug storage room
Auditorium

Real-world evidence

Hospitals, observational studies, PSPs and patient-reported outcomes — the same file that proved the trial now proves value to the agency, the HCP, the payer and the patient.

Home nursing

Study drug at the bedside, biologic sampling, and forty-seven mobile clinicians — so the protocol does not stop at the site door.

Quality assurance

A quality culture, not a certificate on the wall

Quality assurance in healthcare is a necessity. The Quality Assurance team monitors the Quality Management System, runs regular controls and audits, and keeps processes aligned with ICH guidelines, SOPs, and the ISO stack we hold — 9001, 27001, 37001, 13485 — and YA 4822 for medical-device distribution.

Read quality assurance

Local, national and international legislation
ICH Guidelines and Principles
Ethical, legal and regulatory standards
Standard Operating Procedures
ISO 9001:2015, ISO 27001, ISO 37001, ISO 13485 and YA 4822 requirements
Cyber Vadis assessment — 94.5 GDPR compliance score

ISO 9001:2015

Quality management across every division since 2004.

ISO 27001:2022

Information security management, certified 2022.

ISO 37001:2016

Anti-bribery management systems, certified 2022.

ISO 13485:2016

Quality systems for medical-device design and manufacture.

YA 4822

Good distribution of medical devices — HTCert Δ3(α)4822/2025.

Cyber Vadis

94.5 overall score measuring GDPR technical and organisational measures.

Compliance & ethics

Policies that keep us accountable

Read compliance & ethics

Leadership

The people who lead CORONIS

Chief Executive Officer
Evangelia Koraki
Ms Koraki is the founder and Chief Executive Officer of CORONIS Research S.A. since 2003. She studied Chemistry at the University of Athens and has more than twenty years of management experience in Medical & Regulatory Affairs with companies including Roche, Warner Lambert, Pfizer, and Actelion Pharmaceuticals, including fifteen years of senior responsibility in clinical research.
She is a co-founder of the Hellenic CRO Association (HACRO), established in 2012; she served as Secretary until the end of 2017 and has been President of HACRO since then.
Chief Operating Officer
Harry Therianos
Dr Therianos is the Chief Operating Officer of CORONIS Research S.A. He is board-certified in ophthalmic surgery and a member of the Athens Medical Association and the Hellenic Society of Pharmaceutical Medicine. He has over thirty years of experience in the pharmaceutical industry, with management positions at Lundbeck, Pfizer, GSK, and Eli Lilly.

Talk to us

Contact

From a CRO in Athens to three countries

1997

Established as a CRO in Athens.

2003

Re-branded as CORONIS Research and acquired the Athens premises.

2004

ISO 9001 certified. Bioequivalence unit opened.

2005

Cyprus affiliate founded.

2019

Bulgarian affiliate founded.

2021

Patient support programs launched.

2022

Home nursing in clinical trials. ISO 27001, 37001 and 13485.

A quality culture, not a certificate on the wall

Read quality assurance

Local, national and international legislation

ICH Guidelines and Principles

Ethical, legal and regulatory standards

Standard Operating Procedures

ISO 9001:2015, ISO 27001, ISO 37001, ISO 13485 and YA 4822 requirements

Cyber Vadis assessment — 94.5 GDPR compliance score

The people who lead CORONIS

Chief Executive Officer

Evangelia Koraki

Ms Koraki is the founder and Chief Executive Officer of CORONIS Research S.A. since 2003. She studied Chemistry at the University of Athens and has more than twenty years of management experience in Medical & Regulatory Affairs with companies including Roche, Warner Lambert, Pfizer, and Actelion Pharmaceuticals, including fifteen years of senior responsibility in clinical research.

She is a co-founder of the Hellenic CRO Association (HACRO), established in 2012; she served as Secretary until the end of 2017 and has been President of HACRO since then.

Chief Operating Officer

Harry Therianos

Dr Therianos is the Chief Operating Officer of CORONIS Research S.A. He is board-certified in ophthalmic surgery and a member of the Athens Medical Association and the Hellenic Society of Pharmaceutical Medicine. He has over thirty years of experience in the pharmaceutical industry, with management positions at Lundbeck, Pfizer, GSK, and Eli Lilly.